
Sign up to save your podcasts
Or
Check out our free downloads at nascentmc.com:
See the full write ups for today's episodes at nascentmc.com/podcast
In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from July 31, 2023 – August 4, 2023. Please check back every Monday morning so that you can stay up to date.
Here are the highlights:
· The FDA has approved Zurzuvae, the first oral medication for postpartum depression, showing significant improvement in patient symptoms compared to placebo groups.
· Jemperli, a PD-1 inhibitor, has been approved by the FDA for use with chemotherapy in adult patients with primary advanced or recurrent endometrial cancer with specific mutations. The drug is already approved for use as a single agent in similar cases and is now indicated for use in the first-line setting, with discussions for a broader indication underway with the FDA.
· The FDA has approved the oral drug Lonsurf, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer previously treated with specific chemotherapy and targetd therapies. Lonsurf, initially approved as a single agent in 2015, is also approved for advanced metastatic gastric or gastroesophageal junction adenocarcinoma.
· The FDA has approved an expanded indication for Ervebo, a vaccine now indicated for the prevention of disease caused by Zaire ebolavirus for individuals aged 12 months and older.
Did you know, you can access our nascentmc.com/podcast page and search the notes from this podcast! So for example, if you search a term like "diabetes" it will bring up all the diabetes related therapeutic agents approved since the first episode on May 15 of this year. We're also including the prescribing information with each summary too. Check it out at nascentmc.com/podcast.
Intro and outro music
Garden Of Love by Pk jazz Collective
5
44 ratings
Check out our free downloads at nascentmc.com:
See the full write ups for today's episodes at nascentmc.com/podcast
In this week's New FDA Approval's podcast episode, Dr. Emma Hitt Nichols discusses the latest FDA approvals from July 31, 2023 – August 4, 2023. Please check back every Monday morning so that you can stay up to date.
Here are the highlights:
· The FDA has approved Zurzuvae, the first oral medication for postpartum depression, showing significant improvement in patient symptoms compared to placebo groups.
· Jemperli, a PD-1 inhibitor, has been approved by the FDA for use with chemotherapy in adult patients with primary advanced or recurrent endometrial cancer with specific mutations. The drug is already approved for use as a single agent in similar cases and is now indicated for use in the first-line setting, with discussions for a broader indication underway with the FDA.
· The FDA has approved the oral drug Lonsurf, in combination with bevacizumab, for the treatment of adult patients with metastatic colorectal cancer previously treated with specific chemotherapy and targetd therapies. Lonsurf, initially approved as a single agent in 2015, is also approved for advanced metastatic gastric or gastroesophageal junction adenocarcinoma.
· The FDA has approved an expanded indication for Ervebo, a vaccine now indicated for the prevention of disease caused by Zaire ebolavirus for individuals aged 12 months and older.
Did you know, you can access our nascentmc.com/podcast page and search the notes from this podcast! So for example, if you search a term like "diabetes" it will bring up all the diabetes related therapeutic agents approved since the first episode on May 15 of this year. We're also including the prescribing information with each summary too. Check it out at nascentmc.com/podcast.
Intro and outro music
Garden Of Love by Pk jazz Collective
129 Listeners
325 Listeners
493 Listeners
652 Listeners
3,332 Listeners
90 Listeners
122 Listeners
28 Listeners
716 Listeners
318 Listeners
559 Listeners
88 Listeners
17 Listeners
15 Listeners
3 Listeners